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ABSTRACT 
Allopathic drugs used as hypolipidemic agents have number of unwanted effects. Herbal therapy for 
Hyperlipidemia is getting attention due to their less frequent side effects. In this study we have compared 
hypolipidemic effects of Fenofibrate 40 mg with Nigella sativa. Seventy-five hyperlipidemic patients from 
National Hospital Lahore were enrolled for study. Consent was taken from all enrolled participants and were 
divided in three equal numbers i.e.; twenty-five in each group. Group 1 was on Nigella sativa, group 2 was on 
Gemfibrozil and third group was on placebo therapy. They were advised to take drugs for two months. After 
completion of study pretreatment and post treatment values of LDL cholesterol were analyzed statistically. In 
25 patients who were on Nigella sativa, their LDL cholesterol decreased from 191.14±3.45 to 159.40±2.98 mg/dl. 
31.7 mg/dl LDL reduction was observed when compared with placebo group. In 25 patients who were on 
Fenofibrate 40 mg, their LDL cholesterol decreased from 197.77±3.91 mg/dl to 159.62±2.20 mg/dl. LDL 
reduction in this group was 38.2 mg/dl. These changes are highly significant with p-values of <0.001. We 
concluded from this study that hypolipidemic characteristic of Nigella sativa is comparable and therapeutically 
as effective as traditionally used hypolipidemic medication Fenofibrate. 
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INTRODUCTION 
In human body free radicals are formed in consequence of various metabolic processes. If 
there is abundance of low-density lipoprotein particles in plasma, there are chances of risk to 
develop CAD (coronary artery disease) when free radicals interact with LDL particles. CAD may 
lead to morbidity and mortality due to cardiac arrest in human population [1-3]. In some 
cases, atherosclerotic plaques may totally block the blood supply to the myocytes, causing 
cardiac attack [4]. Atherosclerotic plaque contains calcium, cholesterol, free fatty acids, and 
macrophages in variable amount. These plaques are of two types i.e.; hard and soft. Soft 
plaques are more vulnerable than hard and can rupture easily as compared to hard one. There 
are risks for ischemic stroke too if blood supply to neurons ensues [5]. Hypolipidemic drugs 
can be used to prevent hyperlipemia, CAD, heart arrhythmias and cardiac arrest. Allopathic 
drugs used to prevent or cure Hyperlipidemia include Statins, Fibrates, niacin and bile acid 
binding resins [6]. If Fenofibrate is used, there is increased synthesis of high-density 
lipoprotein particles in plasma. In patients suffering from hyperlipidemia, Fenofibrate 
enhances turnover of tissue cholesterol, thus reducing lipoprotein particles. Apoproteins in 
LDL are also changed by Fenofibrates leading to high affinity for the low-density lipoprotein 
receptors to LDL particles [7, 8]. Nigella sativa or kalonji contains conjugated linoleic acid, 
thymoquinone, melanthin, nigilline, damascenine, and trans-anethole. Thymoquinone (TQ) 
extracted from Nigella sativa (kalonji) inhibits iron-dependent microsomal lipid peroxidation. 
Stimulation of polymorphonuclear leukocytes with thymoquinone works as protector against 
damaging effects of free radicles generated biochemically in human body [9,10]. 
Prehistorically Nigella sativa is being used to treat, inflammation, high plasma lipids, high 
blood pressure, asthma, diabetes mellitus, arthritis, and gastrointestinal problems [11-14]. In 
this study we tried to compare hypolipidemic potential of Nigella sativa with Fenofibrate. 
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DESIGN & METHODOLOGY 
Design of Research Work 
It was single blind placebo-controlled study.  
 
Venue 
The research work was conducted at National Hospital Lahore, Pakistan from February to July 
2015.  
 
Sample Size and Inclusion Criteria  
75 hyperlipidemic patients were enrolled whose age range was from 18 to 70 years. Well 
explained, written consent was taken from all participants. EXCLUSION CRITERIA: 
Hypothyroidism, peptic ulcer, diabetes mellitus type-I and type-2, any major cardiac, renal 
and hepatic illness.   
 
Grouping and Methodology 
Enrolled patients were divided in three equal numbers i.e.; 25 patients in Group-1, 25 in 
Group-2, and 25 patients in Group-3.  Baseline LDL -cholesterol of all patients was determined 
in Biochemistry laboratory of the hospital. Separate folder was designed for each enrolled 
patient, in which their personal data, medical history, laboratory reports, follow-up visit 
proforma were kept. Their plasma LDL-cholesterol was calculated by Friedwald formula [7] 
(LDL-C = Total cholesterol-(Triglycerides/5 + HDL-C). 25 patients of group-1 were advised to 
take eight grams of Kalonji (Nigella sativa) in two divided doses for two months. 25 patients 
of group-2 were advised to use 40 mg Fenofibrate tablets twice daily for two months. 25 
patients of group-3 were advised to take Capsule (Placebo capsule containing grinded wheat 
powder) twice daily for two months. They were advised to take their medication after 
breakfast and after dinner. All participants were convinced to go for 20 minutes brisk walk at 
morning or evening time. Fortnight follow-up visit was arranged for all participants. After two 
months research period their lipid profile was determined in same laboratory of the hospital.  
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Statistical Analysis 
Mean values of LDL-cholesterol ±SEM were analysed statistically by using SPSS 2014 version. 
Paired t-test was applied to analyse pre-treatment and post treatment values. p<0.05 was 
minimum probability value to determine statistical significance. p<0.05 was considered as 
non-significant change in tested parameter. p>0.001 was marked as highly significant change 
in the tested parameter.  
 
 
RESULT 
When results were compiled and statistically analyzed, it was observed that Nigella sativa and 
Fenofibrate 40 mg decreased LDL-cholesterol significantly. Nigella sativa decreased LDL 
cholesterol from 191.14±3.45 mg/dl to 159.40±2.98 mg/dl. This change in mean values was 
31.7 mg/dl with highly significant p-value of <0.001. Fenofibrate decreased LDL cholesterol 
from 197.77±3.91 mg/dl to 159.62±2.20 mg/dl. In mean values this change was 38.2 mg/dl 
with highly significant p-value of <0.001. Placebo group showed LDL cholesterol reduction 
from 163.10±1.45 mg/dl to 159.40±1.77 mg/dl. This change in mean values was 3.7 mg/dl, 
with non-significant p-value of >0.05.   
 
Table illustrating LDL-cholesterol values before and after treatment with Nigella sativa, 
Fenofibrate 40 mg and placebo with their p-values  
Drug At day-0 At day-60 Change in mg/dl p-values 
NS 191.14±3.45 159.40±2.98 31.7 <0.001 
FF 197.77±3.91 159.62±2.20 38.2 <0.001 
PL 163.10±1.45 159.40±1.77 3.7 >0.05 
Abbreviations: NS stands for Nigella sativa, FF stands for Fenofibrate, PL stands for placebo 
group. All parameters are measured in mg/dl, P-value <0.01 stands for significant change, P-
value >0.05 stands for non-significant change. 
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DISCUSSION 
Normal plasma lipid levels are required to keep heart healthy. Statins, Fibrates, Bile Acid 
Binding Resins, and Niacin (Vitamin B3) are used as hypolipidemic medicines in allopathy, but 
all these have unwanted effects. In Ayurveda discipline of therapeutics, various herbs, fruits 
and vegetables are used to reduce bad-cholesterol (LDL-C) and to increase good-cholesterol 
(HDL-C). In various research study results Kalonji is labeled as hypolipidemic therapeutic agent 
but little research work is done on comparison of its hypolipidemic potential with allopathy 
related hypolipidemic medicines. This research was targeted to compare its hypolipidemic 
characteristics with one of the Fibrate i.e. Fenofibrate 40 mg. In our results it was observed 
that Kalonji or Nigella sativa reduced LDL-cholesterol 31.7 mg/dl which is almost 16.58 % 
reduction in the parameter. This change is highly significant (p<0.001). Same highly significant 
change (p<0.001) was observed by using Fenofibrate 40 mg in 25 hyperlipidemic patients.  
Results of study conducted by Osenda M. et al. [15] also support our observation and results. 
Fandelaki I. et al. [16] observed that Kalonji increase HDL-cholesterol, and decrease LDL-
cholesterol, triglycerides, and plasma total cholesterol in 4 weeks therapy if brisk walk is 
added with this medication.  Alberti K. et al. [17] stated that there are various mechanisms by 
which seeds of the herb decrease LDL-cholesterol and decrease triglycerides. Duverger A. et 
al. [18] explained that NS inhibit enterohepatic circulation, leading to decreased synthesis of 
cholesterol by HMG-CoA reductase pathway. Harnandez M. et al. [19] observed lesser 
hypolipidemic effects of Kalonji when used in 15 hyperlipidemic patients for two weeks. They 
recommended to use herb for prolonged time as lipoproteins and their structural apoproteins 
take time to be synthetize in hepatic cells. Harnandez M. et al. [20] had explained that kalonji 
is useful for increasing HDL-cholesterol. Haddad P. et al. [21] wrote in their article that kalonji 
decrease plasma TG (triglycerides) rich lipoproteins (VLDL), thus neutral fat is reduced. 
Exchange of neutral fats between high density lipoproteins and very low-density lipoproteins 
in plasma occurs by use of Kalonji [22].  
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